Exicure Inc Share Price Other OTC
Equities
US30205M1018
Biotechnology & Medical Research
Sales 2021 | -5L -4.03Cr | Sales 2022 | 2.88Cr 240.46Cr | Capitalization | 57.09L 48Cr |
---|---|---|---|---|---|
Net income 2021 | -6.4Cr -533.87Cr | Net income 2022 | -20L -17Cr | EV / Sales 2021 | 8.21 x |
Net cash position 2021 | 2.44Cr 203.58Cr | Net cash position 2022 | 12.71L 11Cr | EV / Sales 2022 | 0.15 x |
P/E ratio 2021 |
-0.28
x | P/E ratio 2022 |
-2.06
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 54.96% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 24/23/24 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/22/01 |
Investor Relations Contact | 47 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/22/01 |
Paul Kang
CEO | Chief Executive Officer | 63 | 24/23/24 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 23/23/23 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 11TCr | |
+11.38% | 11TCr | |
-12.64% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.58% | 1.68TCr | |
+37.41% | 1.25TCr | |
-23.95% | 808.97Cr |